Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier

Molecular and Cellular Neuroscience

Volumn 56, Issue , 2013, Pages 255-262

  Bachmeier, Corbin ^a   Beaulieu Abdelahad, David ^a   Mullan, Michael ^a   Paris, Daniel ^a  

^a ROSKAMP INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Blood brain barrier; Cannabinoid; Clearance; Low density lipoprotein receptor related protein 1

Indexed keywords

AMYLOID BETA PROTEIN; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CLEARANCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRANSCYTOSIS;

ALZHEIMER'S DISEASE; AMYLOID; BLOOD-BRAIN BARRIER; CANNABINOID; CLEARANCE; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1;

AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; MICE; PEPTIDE FRAGMENTS; RECEPTORS, LDL; TRANSCYTOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84880934071     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2013.06.004     Document Type: Article

References (60)

1. Aguado T., Romero E., Monory K., Palazuelos J., Sendtner M., Marsicano G., Lutz B., Guzman M., Galve-Roperh I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem. 2007, 282:23892-23898.
2. Aso E., Palomer E., Juves S., Maldonado R., Munoz F.J., Ferrer I. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. J. Alzheimers Dis. 2012, 30:439-459.
3. Bachmeier C., Mullan M., Paris D. Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood-brain barrier. Cytotechnology 2010, 62:519-529.
4. Bachmeier C.J., Beaulieu-Abdelahad D., Mullan M.J., Paris D. Epitope-dependent effects of beta-amyloid antibodies on beta-amyloid clearance in an in vitro model of the blood-brain barrier. Microcirculation 2011, 18:373-379.
5. Bachmeier C., Paris D., Beaulieu-Abdelahad D., Mouzon B., Mullan M., Crawford F. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener. Dis. 2013, 11:13-21.
6. Bisogno T., De Petrocellis L., Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr. Pharm. Des. 2002, 8:533-547.
7. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 2005, 517:174-181.
8. Campbell V.A., Gowran A. Alzheimer's disease; taking the edge off with cannabinoids?. Br. J. Pharmacol. 2007, 152:655-662.
9. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., Goate A.M., Bales K.R., Paul S.M., Bateman R.J., Holtzman D.M. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
10. Chen R., Zhang J., Wu Y., Wang D., Feng G., Tang Y.P., Teng Z., Chen C. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2012, 2:1329-1339.
11. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398.
12. Deane R., Sagare A., Zlokovic B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr. Pharm. Des. 2008, 14:1601-1605.
13. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10819-10824.
14. Donev R., Kolev M., Millet B., Thome J. Neuronal death in Alzheimer's disease and therapeutic opportunities. J. Cell. Mol. Med. 2009, 13:4329-4348.
15. Du H., Chen X., Zhang J., Chen C. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma. Br. J. Pharmacol. 2011, 163:1533-1549.
16. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J., Shytle R.D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2005, 2:29.
17. Farooqui A.A., Liss L., Horrocks L.A. Stimulation of lipolytic enzymes in Alzheimer's disease. Ann. Neurol. 1988, 23:306-308.
18. Galasko D., Montine T.J. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark. Med. 2010, 4:27-36.
19. Gauthier A., Vassiliou G., Benoist F., McPherson R. Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2003, 278:11945-11953.
20. Gauthier K.M., Baewer D.V., Hittner S., Hillard C.J., Nithipatikom K., Reddy D.S., Falck J.R., Campbell W.B. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H1344-H1351.
21. Gertsch J., Anavi-Goffer S. Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors?. J. Neuroinflammation 2012, 9:135.
22. Golech S.A., McCarron R.M., Chen Y., Bembry J., Lenz F., Mechoulam R., Shohami E., Spatz M. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 2004, 132:87-92.
23. Haghani M., Shabani M., Javan M., Motamedi F., Janahmadi M. CB1 cannabinoid receptor activation rescues amyloid beta-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cell. Physiol. Biochem. 2012, 29:391-406.
24. Harvey B.S., Ohlsson K.S., Maag J.L., Musgrave I.F., Smid S.D. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro. Neurotoxicology 2012, 33:138-146.
25. Ho W.S., Randall M.D. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br. J. Pharmacol. 2007, 150:641-651.
26. Horvath B., Magid L., Mukhopadhyay P., Batkai S., Rajesh M., Park O., Tanchian G., Gao R.Y., Goodfellow C.E., Glass M., Mechoulam R., Pacher P. A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br. J. Pharmacol. 2012, 165:2462-2478.
27. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 2005, 115:3104-3116.
28. Jin K., Xie L., Kim S.H., Parmentier-Batteur S., Sun Y., Mao X.O., Childs J., Greenberg D.A. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol. 2004, 66:204-208.
29. Kirilly E., Gonda X., Bagdy G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol. (Oxf.) 2012, 205:41-60.
30. Krohn M., Lange C., Hofrichter J., Scheffler K., Stenzel J., Steffen J., Schumacher T., Bruning T., Plath A.S., Alfen F., Schmidt A., Winter F., Rateitschak K., Wree A., Gsponer J., Walker L.C., Pahnke J. Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J. Clin. Invest. 2011, 121:3924-3931.
31. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 2002, 3:862-872.
32. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
33. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavon F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5:37-44.
34. Long J.Z., Nomura D.K., Vann R.E., Walentiny D.M., Booker L., Jin X., Burston J.J., Sim-Selley L.J., Lichtman A.H., Wiley J.L., Cravatt B.F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20270-20275.
35. Maccarrone M., Fiori A., Bari M., Granata F., Gasperi V., De Stefano M.E., Finazzi-Agro A., Strom R. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb. Haemost. 2006, 95:117-127.
36. Marchalant Y., Baranger K., Wenk G.L., Khrestchatisky M., Rivera S. Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention?. J. Neuroinflammation 2012, 9:10.
37. Marrs W.R., Blankman J.L., Horne E.A., Thomazeau A., Lin Y.H., Coy J., Bodor A.L., Muccioli G.G., Hu S.S., Woodruff G., Fung S., Lafourcade M., Alexander J.P., Long J.Z., Li W., Xu C., Moller T., Mackie K., Manzoni O.J., Cravatt B.F., Stella N. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 2010, 13:951-957.
38. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., Van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
39. Martin-Moreno A.M., Brera B., Spuch C., Carro E., Garcia-Garcia L., Delgado M., Pozo M.A., Innamorato N.G., Cuadrado A., de Ceballos M.L. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 2012, 9:8.
40. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
41. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
42. Mehta P.D. Amyloid beta protein as a marker or risk factor of Alzheimer's disease. Curr. Alzheimer Res. 2007, 4:359-363.
43. Milton N.G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 2002, 332:127-130.
44. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C., Ward A.M., Hahn Y.K., Lichtman A.H., Conti B., Cravatt B.F. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
45. Nordberg A. Amyloid imaging in Alzheimer's disease. Neuropsychologia 2008, 46:1636-1641.
46. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 2007, 152:576-582.
47. Pan B., Wang W., Zhong P., Blankman J.L., Cravatt B.F., Liu Q.S. Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. J. Neurosci. 2011, 31:13420-13430.
48. Paris D., Bachmeier C., Patel N., Quadros A., Volmar C.H., Laporte V., Ganey J., Beaulieu-Abdelahad D., Ait-Ghezala G., Crawford F., Mullan M.J. Selective antihypertensive dihydropyridines lower abeta accumulation by targeting both the production and the clearance of abeta across the blood-brain barrier. Mol. Med. 2011, 17:149-162.
49. Piro J.R., Benjamin D.I., Duerr J.M., Pi Y., Gonzales C., Wood K.M., Schwartz J.W., Nomura D.K., Samad T.A. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 2012, 1:617-623.
50. Rockwell C.E., Snider N.T., Thompson J.T., Vanden Heuvel J.P., Kaminski N.E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 2006, 70:101-111.
51. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., Marky A., Lenting P.J., Wu Z., Zarcone T., Goate A., Mayo K., Perlmutter D., Coma M., Zhong Z., Zlokovic B.V. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 2007, 13:1029-1031.
52. Sarne Y., Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:677-684.
53. Savinainen J.R., Saario S.M., Laitinen J.T. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol. (Oxf.) 2012, 204:267-276.
54. Scotter E.L., Abood M.E., Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol. 2010, 160:480-498.
55. Shen M., Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 1998, 54:459-462.
56. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106:1489-1499.
57. Sugiura T., Kishimoto S., Oka S., Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 2006, 45:405-446.
58. Van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., Micale V., Steardo L., Drago F., Iuvone T., Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 2006, 63:1410-1424.
59. Weller R.O., Boche D., Nicoll J.A. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 2009, 118:87-102.
60. Wu J., Bie B., Yang H., Xu J.J., Brown D.L., Naguib M. Activation of the CB(2) receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging 2013, 34:791-804.